Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis

Toxicology and Applied Pharmacology

Volumn 275, Issue 2, 2014, Pages 176-181

  Chen, Yan ^a   Li, Zheng ^a   He, Yan ^a   Shang, Dandan ^a   Pan, Jigang ^a   Wang, Hongmei ^a   Chen, Huamei ^a   Zhu, Zhuxia ^a   Wan, Lei ^a   Wang, Xudong ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Calpain; Cell adhesion; Fulvestrant; G protein coupled estrogen receptor 30

Indexed keywords

BREAST CANCER; CALPAIN; CELL ADHESION; FULVESTRANT; G PROTEIN COUPLED ESTROGEN RECEPTOR 30;

BREAST NEOPLASMS; CALPAIN; CELL ADHESION; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE SILENCING; HUMANS; LAMININ; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; PHOSPHORYLATION; PROTEOGLYCANS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84894053614     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.01.005     Document Type: Article

References (37)

1. Acconcia F., Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006, 238:1-14. 10.1016/j.canlet.2005.06.018.
2. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S., Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007, 67:1859-1866. 10.1158/0008-5472.CAN-06-2909.
3. Ariazi E.A., Brailoiu E., Yerrum S., Shupp H.A., Slifker M.J., Cunliffe H.E., Black M.A., Donato A.L., Arterburn J.B., Oprea T.I., Prossnitz E.R., Dun N.J., Jordan V.C. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010, 70:1184-1194. 10.1158/0008-5472.CAN-09-3068.
4. Baki A., Tompa P., Alexa A., Molnar O., Friedrich P. Autolysis parallels activation of mu-calpain. Biochem. J. 1996, 318(Pt 3):897-901. (http://www.ncbi.nlm.nih.gov/pubmed/8836135).
5. Bieche I., Parfait B., Laurendeau I., Girault I., Vidaud M., Lidereau R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001, 20:8109-8115. 10.1038/sj.onc.1204917.
6. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168. 10.1016/j.semcancer.2010.05.002.
7. Braun C., Engel M., Seifert M., Theisinger B., Seitz G., Zang K.D., Welter C. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. Int. J. Cancer 1999, 84:6-9. (http://www.ncbi.nlm.nih.gov/pubmed/9988224).
8. Brooks S.A., Lomax-Browne H.J., Carter T.M., Kinch C.E., Hall D.M. Molecular interactions in cancer cell metastasis. Acta Histochem. 2010, 112:3-25. 10.1016/j.acthis.2008.11.022.
9. Du G.Q., Zhou L., Chen X.Y., Wan X.P., He Y.Y. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem. Biophys. Res. Commun. 2012, 420:343-349. 10.1016/j.bbrc.2012.02.161.
10. Fan D.G., Dai J.Y., Tang J., Wu M.M., Sun S.G., Jiang J.L., Fan Q.Y. Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. Cell Biol. Int. 2009, 33:1263-1267. 10.1016/j.cellbi.2009.08.014.
11. Ferreira E., Cronje M.J. Selection of suitable reference genes for quantitative real-time PCR in apoptosis-induced MCF-7 breast cancer cells. Mol. Biotechnol. 2012, 50:121-128. 10.1007/s12033-011-9425-3.
12. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660. (http://www.ncbi.nlm.nih.gov/pubmed/11043579).
13. Filardo E.J., Graeber C.T., Quinn J.A., Resnick M.B., Giri D., DeLellis R.A., Steinhoff M.M., Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 2006, 12:6359-6366. 10.1158/1078-0432.CCR-06-0860.
14. Glading A., Bodnar R.J., Reynolds I.J., Shiraha H., Satish L., Potter D.A., Blair H.C., Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol. Cell. Biol. 2004, 24:2499-2512. (http://www.ncbi.nlm.nih.gov/pubmed/14993287).
15. Goto N., Hiyoshi H., Ito I., Tsuchiya M., Nakajima Y., Yanagisawa J. Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-beta signaling pathway. Cancer Sci. 2011, 102:1501-1508. 10.1111/j.1349-7006.2011.01977.x.
16. Hou J., Wang X., Li Y., Liu X., Wang Z., An J., Yang L., He Y. 17beta-estradiol induces both up-regulation and processing of cyclin E in a calpain-dependent manner in MCF-7 breast cancer cells. FEBS Lett. 2012, 586:892-896. 10.1016/j.febslet.2012.02.018.
17. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br. J. Cancer 2004, 90(Suppl. 1):S15-S18. 10.1038/sj.bjc.6601632.
18. Keyomarsi K., Tucker S.L., Buchholz T.A., Callister M., Ding Y., Hortobagyi G.N., Bedrosian I., Knickerbocker C., Toyofuku W., Lowe M., Herliczek T.W., Bacus S.S. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 2002, 347:1566-1575. 10.1056/NEJMoa021153.
19. Li Y., Chen Y., Zhu Z.X., Liu X.H., Yang L., Wan L., Lei T.W., Wang X.D. 4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells. Toxicology 2013, 309:61-65. 10.1016/j.tox.2013.04.012.
20. Libertini S.J., Robinson B.S., Dhillon N.K., Glick D., George M., Dandekar S., Gregg J.P., Sawai E., Mudryj M. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res. 2005, 65:10700-10708. 10.1158/0008-5472.CAN-05-1666.
21. Liu Q., Li J.G., Zheng X.Y., Jin F., Dong H.T. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin. Med. J. (Engl.) 2009, 122:2763-2769. (http://www.ncbi.nlm.nih.gov/pubmed/19951611).
22. Maggiolini M., Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J. Endocrinol. 2010, 204:105-114. 10.1677/JOE-09-0242.
23. Marsaud V., Gougelet A., Maillard S., Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 2003, 17:2013-2027. 10.1210/me.2002-0269.
24. Marshall A.M., McClaine R.J., Gurusamy D., Gray J.K., Lewnard K.E., Khan S.A., Waltz S.E. Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice. Mol. Cancer 2012, 11:2. 10.1186/1476-4598-11-2.
25. Maynadier M., Chambon M., Basile I., Gleizes M., Nirde P., Gary-Bobo M., Garcia M. Estrogens promote cell-cell adhesion of normal and malignant mammary cells through increased desmosome formation. Mol. Cell. Endocrinol. 2012, 364:126-133. 10.1016/j.mce.2012.08.016.
26. Moser M., Legate K.R., Zent R., Fassler R. The tail of integrins, talin, and kindlins. Science 2009, 324:895-899. 10.1126/science.1163865.
27. Pandey D.P., Lappano R., Albanito L., Madeo A., Maggiolini M., Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009, 28:523-532. 10.1038/emboj.2008.304.
28. Perey L., Paridaens R., Hawle H., Zaman K., Nole F., Wildiers H., Fiche M., Dietrich D., Clement P., Koberle D., Goldhirsch A., Thurlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 2007, 18:64-69. 10.1093/annonc/mdl341.
29. Qi Q., Lu N., Wang X.T., Gu H.Y., Yang Y., Liu W., Li C., You Q.D., Guo Q.L. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem. Cell Biol. 2008, 86:386-395. 10.1139/o08-104.
30. Saha Roy S., Vadlamudi R.K. 2012. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast. Cancer 2012, 10.1155/2012/654698.
31. Schmidmaier R., Baumann P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr. Med. Chem. 2008, 15:978-990. (http://www.ncbi.nlm.nih.gov/pubmed/18393855).
32. Smith R.A., Saslow D., Sawyer K.A., Burke W., Costanza M.E., Evans W.P., Foster R.S., Hendrick E., Eyre H.J., Sener S., American Cancer Society High-Risk Work, G., American Cancer Society Screening Older Women Work, G., American Cancer Society Mammography Work, G., American Cancer Society Physical Examination Work, G., American Cancer Society New Technologies Work, G., American Cancer Society Breast Cancer Advisory, G. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J. Clin. 2003, 53:141-169. (http://www.ncbi.nlm.nih.gov/pubmed/12809408).
33. Storr S.J., Carragher N.O., Frame M.C., Parr T., Martin S.G. The calpain system and cancer. Nat. Rev. Cancer 2011, 11:364-374. 10.1038/nrc3050.
34. Storr S.J., Lee K.W., Woolston C.M., Safuan S., Green A.R., Macmillan R.D., Benhasouna A., Parr T., Ellis I.O., Martin S.G. Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann. Oncol. 2012, 23:2289-2296. 10.1093/annonc/mds176.
35. Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Ando S., Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 2006, 20:631-646. 10.1210/me.2005-0280.
36. Wang X.D., Rosales J.L., Magliocco A., Gnanakumar R., Lee K.Y. Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. Oncogene 2003, 22:769-774. 10.1038/sj.onc.1206166.
37. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276:35684-35692. 10.1074/jbc.M101097200.